Protoporphyrin IX photodynamic therapy for synovitis

Area of Science:

• Biomedical Engineering
• Photochemistry
• Rheumatology

Background:

• Inflammation in arthritic diseases leads to synovial changes.
• Photodynamic therapy (PDT) utilizes photosensitizers to induce cell death upon light activation.
• Protoporphyrin IX (PpIX) is a photosensitizer that can be generated from 5-aminolevulinic acid hexyl ester (h-ALA).

Purpose of the Study:

• To investigate the conditions for synovial accumulation of PpIX.
• To evaluate PDT-induced synovial cytotoxicity in vitro and in vivo.
• To assess the potential of PDT for photodynamic synovectomy in arthritic conditions.

Main Methods:

• Incubation of synovial tissues from mice with antigen-induced arthritis (AIA) with varying concentrations of h-ALA.
• Assessment of PDT-induced cell death using Sytox green fluorescence.
• Intraarticular injection of h-ALA followed by PDT in AIA mouse models, with evaluation of joint inflammation via technetium scintigraphy and histology.
• In vitro analysis of PDT-induced cytotoxicity in synovial biopsy samples from osteoarthritis (OA) and rheumatoid arthritis (RA) patients.

Main Results:

• h-ALA was converted to PpIX in inflamed synovium from both mice and humans.
• PDT induced significant cell death in synovial tissues, confirmed by Sytox green staining.
• PDT treatment in the AIA mouse model led to a significant reduction in joint damage.
• RA synovial tissues exhibited higher PpIX concentrations post-h-ALA incubation compared to OA tissues.
• PpIX localized to the synovial lining layer, endothelial cells, and macrophages, mediating cell death after PDT.

Conclusions:

• PDT demonstrates effective PpIX accumulation in the synovial membrane.
• The findings support PDT as a potential therapeutic strategy for photodynamic synovectomy.
• This approach may offer a novel treatment for inflammatory arthritic diseases.